Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28960
Title: A pilot, feasibility, randomised controlled trial of midodrine as adjunctive vasopressor for low-dose vasopressor-dependent hypotension in intensive care patients: The MAVERIC study.
Austin Authors: Costa-Pinto, Rahul;Yong, Zhen-Ti;Yanase, Fumitaka ;Young, Chelsea;Brown, Alastair;Udy, Andrew;Young, Paul J;Eastwood, Glenn M ;Bellomo, Rinaldo 
Affiliation: Australian and New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia..
Intensive Care
Data Analytics Research and Evaluation (DARE) Centre
Department of Critical Care, Department of Medicine, the University of Melbourne, Parkville, Victoria, Australia..
Department of Intensive Care, Royal Melbourne Hospital, Melbourne, Victoria, Australia..
Medical Research Institute of New Zealand, Private Bag, 7902, Wellington, New Zealand..
Department of Intensive Care, Wellington Regional Hospital, 49 Riddiford Street, Newtown, Wellington, New Zealand..
Department of Intensive Care, The Alfred Hospital, 55 Commercial Road, Melbourne, Victoria, Australia..
Issue Date: Feb-2022
Date: 2021-11-18
Publication information: Journal of critical care 2022; 67: 166-171
Abstract: To assess the feasibility and physiological efficacy of adjunctive midodrine in patients with vasopressor-dependent hypotension. This was a pilot, open label, randomised controlled trial. Patients were enrolled from two tertiary intensive care units on low dose intravenous vasopressor therapy for more than 24 h. We randomly assigned patients to receive either adjunctive midodrine (10 mg every 8 h) or usual care. The primary efficacy outcome was time to cessation of intravenous vasopressor therapy. Secondary outcomes included protocol compliance, ICU and hospital length of stay. We screened 381 patients over 22-months and enrolled 62 (32 in midodrine group, 30 in usual care group). Median time to cessation of vasopressor infusion was 16.5 h for midodrine vs 19 h for usual care (p = 0.22). Time in ICU (50 [25.50, 74.00] hours for midodrine v 59 [38.50, 93.25] hours for usual care, p = 0.14) and hospital length of stay (9 days vs. 7.5 days, p = 0.92) were similar. Protocol compliance was 96.9%. One patient ceased midodrine early due to symptomatic bradycardia. Adjunctive midodrine therapy was feasible with acceptable compliance, duration of therapy, and safety profile. However, at the chosen dose, there was no evidence of physiological or clinical efficacy.
URI: https://ahro.austin.org.au/austinjspui/handle/1/28960
DOI: 10.1016/j.jcrc.2021.11.004
ORCID: 0000-0003-4007-7849
0000-0003-3859-3537
0000-0002-3137-4895
0000-0001-7700-9933
0000-0002-1650-8939
Journal: Journal of critical care
PubMed URL: 34801917
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/34801917/
Type: Journal Article
Subjects: Midodrine
Oral vasopressor
Refractory hypotension
Vasopressor weaning
Appears in Collections:Journal articles

Show full item record

Page view(s)

42
checked on Apr 19, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.